Lara Lipton
Overview
Explore the profile of Lara Lipton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
2799
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
McCracken J, Dabscheck A, Coperchini M, Hornung I, Jalali A, Akers G, et al.
Cancer Rep (Hoboken)
. 2020 Jul;
1(4):e1135.
PMID: 32729198
Background: Thirty-day mortality after chemotherapy has been suggested as a marker of quality in oncology care. Retrospective audits worldwide have put this figure at between 8.1% and 43%, with previous...
12.
Loveday B, Lipton L, Thomson B
Aust J Gen Pract
. 2019 Nov;
48(12):826-831.
PMID: 31774983
Background: Pancreatic cancer has the highest mortality rate among all main cancer types and is the fourth leading cause of cancer death in Australia. Objective: This review focuses on the...
13.
Mendis S, Beck S, Lee B, Lee M, Wong R, Kosmider S, et al.
Asia Pac J Clin Oncol
. 2019 Feb;
15(3):136-143.
PMID: 30761750
Background: Metastatic colorectal cancer (mCRC) patients with a right-sided primary (RC) have an inferior survival to mCRC arising from a left-sided primary (LC). Previous analyses have suggested multiple factors contribute....
14.
Maharaj A, Ioannou L, Croagh D, Zalcberg J, Neale R, Goldstein D, et al.
HPB (Oxford)
. 2018 Oct;
21(4):444-455.
PMID: 30316625
Background: Best practise care optimises survival and quality of life in patients with pancreatic cancer (PC), but there is evidence of variability in management and suboptimal care for some patients....
15.
Semira C, Wong H, Field K, Lee M, Lee B, Nott L, et al.
Intern Med J
. 2018 Sep;
49(4):446-454.
PMID: 30230679
Background: Emerging evidence on the optimal use of chemotherapy and biologics in patients with metastatic colorectal cancer should impact management in routine care. Recent studies have demonstrated benefits for initial...
16.
Lam M, Tran B, Beck S, Tie J, Herath D, Whittle J, et al.
Asia Pac J Clin Oncol
. 2017 Oct;
14(1):84-90.
PMID: 29083093
Aim: Precision oncology involves molecularly matching patients to targeted agents usually in early drug development (EDD) programs. Molecular profiling (MP) identifies actionable targets. Comprehensive commercial MP platforms are costly and...
17.
Abou-Alfa G, Blanc J, Miles S, Ganten T, Trojan J, Cebon J, et al.
Oncologist
. 2017 Jun;
22(7):780-e65.
PMID: 28592620
Lessons Learned: Trebananib leveraging anti-angiogenic mechanism that is distinct from the classic sorafenib anti-vascular endothelial growth factor inhibition did not demonstrate improved progression-free survival at 4 months in patients with...
18.
Au L, Turner N, Wong H, Field K, Lee B, Boadle D, et al.
Asia Pac J Clin Oncol
. 2017 Mar;
14(2):e167-e174.
PMID: 28299879
Aim: Current efforts to understand patient management in clinical practice are largely based on clinician surveys with uncertain reliability. The TRACC (Treatment of Recurrent and Advanced Colorectal Cancer) database is...
19.
Parisot J, Thorne H, Fellowes A, Doig K, Lucas M, McNeil J, et al.
J Pers Med
. 2015 Nov;
5(4):354-69.
PMID: 26529019
"Cancer 2015" is a longitudinal and prospective cohort. It is a phased study whose aim was to pilot recruiting 1000 patients during phase 1 to establish the feasibility of providing...
20.
Gibbs P, Do C, Lipton L, Cade D, Tapner M, Price D, et al.
BMC Cancer
. 2015 Oct;
15:802.
PMID: 26503593
Background: This prospective, open-label phase II study assessed the impact of liver-directed therapy with selective internal radiation therapy (SIRT) and systemic chemotherapy on progression-free survival (PFS) in liver-dominant metastatic pancreatic...